Login to Your Account



Aragon Investors Step Up for Seragon’s $30M Series A

By Jennifer Boggs
Managing Editor

Wednesday, October 16, 2013
newco_news_resized.jpg

Seragon Pharmaceuticals Inc. didn’t have to look very far to find investors for its $30 million Series A round.

The San Diego-based firm, which was spun out from Aragon Pharmaceuticals Inc. just prior to Aragon’s August acquisition by Johnson & Johnson, brought on board Aragon’s investors Venbio, Topspin Fund, Aisling Capital, OrbiMed Advisors and the Column Group. All had participated in Aragon’s $50 million Series D round last year. (See BioWorld Today, Oct. 5, 2012.)

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription